NO20021574L - Fremgangsmåte for å forbedre opplöseligheten av trisykliske aminoalkoholderivater - Google Patents

Fremgangsmåte for å forbedre opplöseligheten av trisykliske aminoalkoholderivater

Info

Publication number
NO20021574L
NO20021574L NO20021574A NO20021574A NO20021574L NO 20021574 L NO20021574 L NO 20021574L NO 20021574 A NO20021574 A NO 20021574A NO 20021574 A NO20021574 A NO 20021574A NO 20021574 L NO20021574 L NO 20021574L
Authority
NO
Norway
Prior art keywords
solubility
improving
amino alcohol
tricyclic amino
alcohol derivatives
Prior art date
Application number
NO20021574A
Other languages
English (en)
Other versions
NO20021574D0 (no
Inventor
Yukio Sumita
Kazumi Suzuki
Masaaki Nasu
Toshimi Hara
Original Assignee
Asahi Chemical Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Chemical Ind filed Critical Asahi Chemical Ind
Publication of NO20021574D0 publication Critical patent/NO20021574D0/no
Publication of NO20021574L publication Critical patent/NO20021574L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Forbindelser nyttige for behandling og forebygging av dia- betes, fedme, hyperlipidemia og så videre er tilveiebrakt i form av orale preparater som fremviser god absorpsjonsevne i fordøyelsessystemet. En fremgangsmåte for bedrng av løse- ligheten av trisyklisk aminoalkoholderivat med den generel- le formel (1) eller salter derav: NHSO2R1 hvori (D R1 representerer en lavere alkylgruppe eller en benzylgrup- pe; * representerer et asymmetrisk karbonatom; R2 representerer et hydrogenatom, et halogenatom eller en hydroksylgruppe; og A representerer en av de følgende grupper: X ^ ' ~**s~ ~w' hvori X representerer NH, O eller S, karakterisert ved an- vendelse av disse derivater eller salter i en amorf til- stand.
NO20021574A 1999-10-04 2002-04-03 Fremgangsmåte for å forbedre opplöseligheten av trisykliske aminoalkoholderivater NO20021574L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28303399 1999-10-04
PCT/JP2000/006715 WO2001025198A1 (fr) 1999-10-04 2000-09-28 Amelioration de la solubilite de derives d'alcools amines tricycliques

Publications (2)

Publication Number Publication Date
NO20021574D0 NO20021574D0 (no) 2002-04-03
NO20021574L true NO20021574L (no) 2002-05-31

Family

ID=17660360

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021574A NO20021574L (no) 1999-10-04 2002-04-03 Fremgangsmåte for å forbedre opplöseligheten av trisykliske aminoalkoholderivater

Country Status (9)

Country Link
EP (1) EP1219604A4 (no)
KR (1) KR20020068513A (no)
CN (1) CN1384821A (no)
AU (1) AU7447900A (no)
BR (1) BR0014469A (no)
CA (1) CA2386373A1 (no)
MX (1) MXPA02003423A (no)
NO (1) NO20021574L (no)
WO (1) WO2001025198A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001252575A1 (en) * 2000-04-28 2001-11-12 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds
WO2002074306A1 (fr) * 2001-03-19 2002-09-26 Asahi Kasei Kabushiki Kaisha Remedes pour la steatose hepatique
MY128945A (en) * 2002-04-16 2007-03-30 Kowa Co Solid dispersion composition
KR101327797B1 (ko) * 2011-08-05 2013-11-25 (주) 제노텍 트리사이클로 화합물 당화 유도체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037362A (en) * 1996-01-10 2000-03-14 Asahi Kasei Kogyo Kabushiki Kaisha Tricyclic compounds and drug compositions containing the same
KR100335169B1 (ko) * 1997-07-03 2002-05-04 야마모토 카즈모토 포화 고리를 갖는 신규한 트리시클릭 화합물 및 이를포함하는 의약 조성물
EP1142883A4 (en) * 1998-12-15 2002-08-21 Asahi Chemical Ind HETEROCYCLIC COMPOUNDS AND MEDICINAL COMPOSITIONS THAT CONTAIN THEM
TW519537B (en) * 1999-03-26 2003-02-01 Asahi Chemical Ind Process for the preparation of tricylic amino-alcohol derivatives
EP1174426A1 (en) * 1999-04-01 2002-01-23 Asahi Kasei Kabushiki Kaisha Method for the preparation of tricyclic amino alcohol derivatives through azides

Also Published As

Publication number Publication date
BR0014469A (pt) 2002-06-11
NO20021574D0 (no) 2002-04-03
CA2386373A1 (en) 2001-04-12
EP1219604A1 (en) 2002-07-03
EP1219604A4 (en) 2005-01-19
MXPA02003423A (es) 2002-08-20
AU7447900A (en) 2001-05-10
CN1384821A (zh) 2002-12-11
KR20020068513A (ko) 2002-08-27
WO2001025198A1 (fr) 2001-04-12

Similar Documents

Publication Publication Date Title
NO996108L (no) 9-oksinerytromycinderivater
DK0870768T3 (da) Azaindol-ethylaminderivater som nikotinacetylcholinreceptor-bindingsmidler
NO20013731L (no) Diazabicykliske derivater som nikotinacetylkolinreseptorligander
BG106524A (en) Piperidine quinolyl propyl derivatives and their use as antibacterial means
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
CA2378148A1 (en) Nematicidal trifluorobutenes
MY119150A (en) Azetidine derivatives, their preparation and medicaments containing them
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
EP1242085A4 (en) BENZIMIDAZOLE COMPOUNDS WITH A NOCICEPTIN RECEPTOR AFFINITY
NO20044501L (no) [1,4] diazenino [6,7,1-IJ] kinolin-derivater som antipsykotis og antifedme-midler
GB9822473D0 (en) Chemical compounds
ZA945621B (en) Novel 5-pyrrolyl-2-pyridylmethylsulfinyl benzimidazole derivatives
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
NO20015172L (no) 1-metyl-erytromycin-derivater
EP1304329A3 (en) Pyridonecarboxylic acid derivatives and their use as antibacterial agents
DK0638075T3 (da) Thiazol- eller imidazolderivater som Maillard-reaktionsinhibitorer
PL326024A1 (en) Novel derivatives of cyclodepsipeptidic substance pf1022
PT1189923E (pt) Derivados aromaticos e heterociclicos de fitosterois e/ ou fitostanois para utilizacao no tratamento ou prevencao de doenca cardiovascular
NO20000957L (no) Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer
BG104447A (en) Biphenylamidine derivatives
NO981393L (no) Guanidinoproteasehemmere
NO20021574L (no) Fremgangsmåte for å forbedre opplöseligheten av trisykliske aminoalkoholderivater
NO315198B1 (no) Fremgangsmåte for fremstilling av et oksazolyletanolderivat
BR0109946A (pt) Derivados de eritromicina substituìda em 6-o tendo tolerância gastrointestinal

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application